All News

Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.

The MALT1 inhibitor demonstrated a favorable safety profile and tolerability in findings from a phase 1 clinical trial presented at the EHA 2025 Congress.

For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.

A total of 35% of patients with fully resected metastatic lung osteosarcoma treated with OST-HER2 achieved 1-year event-free survival.

Use of the novel artificial intelligence–based test may provide a painless, low-cost alternative in bladder cancer screening.

Data support incorporating volumetric PET biomarkers into toxicity risk prediction for patients receiving CAR T-cell therapy for LBCL.

89Zr-DFO-daratumumab shows activity in identifying and localizing multiple myeloma, even in FDG-non-avid cases, per new phase 2 data.

Data from the phase 3 ASTRUM-005 trial support the MHRA’s approval of serplulimab for patients with extensive-stage small cell lung cancer.

Gedatolisib showed promising ORRs when given in combination with darolutamide and trastuzumab biosimilar in mCPRC and mBC, respectively.

Nicholas J. Hornstein, MD, PhD, highlighted results from the phase 3 ATOMIC and CHALLENGE trials in CRC presented at the 2025 ASCO.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Deciding when to use immunotherapy and how to utilize antibody-drug conjugates are complicated processes that require multidisciplinary collaboration to ensure that all patients with breast cancer receive appropriate and efficient care.

According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.

The Adventist Health Study found that patients who were vegetarians had a lower risk of medium-frequency cancers.

68Ga-FAPI-46 PET’s SUVpeak was highest in patients with pancreaticobiliary cancer, sarcoma, lung cancer, and esophageal/gastrointestinal cancer.

Compared with 18F-FDG, the use of 68Ga-NODAGA-LM3 appears to favor bone and brain lesion detection among patients with small cell lung cancer.

Data from part B of the DeFianCe study demonstrate a positive overall response rate trend with sirexatamab plus bevacizumab and chemotherapy.

The FDA had reduced driving and geographic restrictions to 2 weeks for patients with lymphomas and multiple myeloma receiving liso-cel and ide-cel.

Tumor penetration of atigotatug in fuc-GM1-positive lung, liver, and bone lesions was observed in those with extensive-stage small cell lung cancer.

Larger multi-center trials could further elucidate the long-term outcomes of anlotinib plus immune checkpoint inhibition in this patient group.

Findings from the phase 2b ASCEND trial will be presented at the European Society for Medical Oncology Gastrointestinal Cancers Congress on July 2, 2025.

Elraglusib plus gemcitabine and nab-paclitaxel demonstrated a median OS of 12.5 months vs 8.5 months with chemotherapy alone in patients with PDAC.

“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.

Twenty-two of 27 injected tumors across all patients with soft tissue sarcoma in the study showed complete or partial ablation.

Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.

PATHFINDER 2 data build upon bolstered cancer detection rates by the multicancer early detection test found in a previously published PATHFINDER study.